Woburn, MA ProTom International has moved its medtech manufacturing operation to an 11,000 s/f facility. The firm relocated from North Reading to Cummings Properties’ Gill St. technology campus.

Founded in 2008, ProTom International seeks to transform cancer treatment with the Radiance 330, a next-generation proton therapy system. The compact, precision radiation treatment device was first adopted in 2020 at Massachusetts General Hospital, and at Australian Bragg Centre, in Adelaide, Australia.

Cummings Properties leasing director Steve Cusano worked with Jim Boudrot, executive vice president at Hunneman, on the lease.

“We have a strong history of partnering with Jim and the Hunneman team,” said Cusano. “They appreciate our ability to deliver space on an accelerated timeline, which was critical in the case of ProTom International.”

According to Cusano, Cummings completed construction earlier this month to tailor the space for ProTom International’s intended R&D, manufacturing, and administrative functions.

“With a diverse portfolio of 11 million s/f, Cummings can quickly accommodate businesses of all kinds,” said Cusano. “And our efficient in-house design and construction capabilities make leasing with Cummings especially convenient for businesses in the medical, science, and tech industries.”

The town is home to a substantial cluster of technology firms. Among ProTom International’s new neighbors on Gill St. are NanoImaging Services, Covidien, Purinomia Biotech, Kyinno Biotech, Leveragen, and more.

Cummings Properties manages 11 million s/f of commercial space in 11 communities north and west of Boston. Most of these properties are owned by Cummings Foundation, with 100% of all rental profits supporting hundreds of local nonprofits. The Cummings organization just announced $30 million in grants to greater Boston nonprofits, and it has awarded more than $500 million to date.